|Bid||0.00 x 150000|
|Ask||0.00 x 150000|
|Day's Range||127.50 - 127.50|
|52 Week Range||126.50 - 165.00|
|PE Ratio (TTM)||-9.73|
|Earnings Date||Sep 8, 2017 - Sep 11, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Verseon has announced the launch of a drug program developing oral treatments for hereditary angioedema , a rare, life-threatening genetic disease. In their interim report published yesterday, the Company presented data from a well-established HAE disease model which demonstrate the efficacy of their plasma kallikrein inhibitors in reducing swelling.
Verseon presented preclinical data on multiple novel drug candidates for the treatment of diabetic macular edema at the 2017 BIO International Conference in San Diego, last week.